About Us

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries).

Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.

https://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Large.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Small.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/22ArctP750_large.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/22ArctP750_thumb.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF_230.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/ArcBuilding_Final.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/building_external_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF_230.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-exterior.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main_office_exterior_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-interior-tag-line.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/building_tagline_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo-scaled-1.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo-scaled-1.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo_thumbnail.jpg
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
June 1, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 3, 2013
With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego
READ MORE
June 3, 2013
RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round
READ MORE
June 3, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech
READ MORE
June 4, 2013
Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding
READ MORE
June 4, 2013
Startup Arcturus Pulls in $1.3M in Seed Money amid Renewed Interest in RNAi
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
READ MORE
August 14, 2013
Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina
READ MORE
August 15, 2013
San Diego upstart acquires RNA tech from cash-strapped Marina Biotech
READ MORE
August 15, 2013
San Diego Life Sciences Roundup: Vical, Fate, Arcturus, and More
READ MORE
August 15, 2013
Arcturus Therapeutics Acquires Patent Portfolio from Marina Biotech
READ MORE
August 15, 2013
Marina Sells UNA Patent Estate to Arcturus as It Looks to Resume Operations
READ MORE
July 24, 2023
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
READ MORE
August 7, 2023
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
READ MORE
August 14, 2023
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
READ MORE
August 17, 2023
Arcturus Therapeutics to Attend Upcoming Investor Conferences
READ MORE
September 5, 2023
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
READ MORE
September 19, 2023
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
READ MORE
September 26, 2023
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
READ MORE
October 4, 2023
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
READ MORE
October 23, 2023
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
READ MORE
October 25, 2023
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
READ MORE
November 14, 2023
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
READ MORE
November 27, 2023
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
READ MORE
November 28, 2023
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
READ MORE
December 4, 2023
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
READ MORE
December 21, 2023
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
READ MORE
February 5, 2024
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
READ MORE
February 20, 2024
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
READ MORE
February 22, 2024
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
READ MORE
February 26, 2024
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
READ MORE
March 7, 2024
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
READ MORE